Lobbying registration dated 2026-01-20
Registrant: RAMI FAYED
Client: AbbVie Corporation
Targeted institutions:
Atlantic Canada Opportunities Agency (ACOA)
Canadian Institutes of Health Research (CIHR)
Royal Canadian Mounted Police (RCMP)
Treasury Board Of Canada Secretariat (TBS)
Public Services and Procurement Canada (PSPC)
Indigenous Services Canada (ISC)
Invest in Canada Hub
Global Affairs Canada (GAC)
Patented Medicine Prices Review Board (PMPRB)
Intergovernmental Affairs Secretariat (IGA)
Finance Canada (FIN)
House of Commons
National Defence (DND)
Immigration and Refugee Board (IRB)
Employment and Social Development Canada (ESDC)
Veterans Affairs Canada (VAC)
National Research Council (NRC)
Public Health Agency of Canada (PHAC)
Privy Council Office (PCO)
Senate of Canada
Health Canada (HC)
Correctional Service of Canada (CSC)
Prime Minister's Office (PMO)
Innovation, Science and Economic Development Canada (ISED)
Acts: Patent Act
Government funding received:
Lobbying activity details:
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.
Communications with Health Canada regarding the evolution of the regulatory framework to address advanced therapeutic products.
Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials.
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.
Communications with Heath Canada regarding modernization of the medical devices regulatory framework.
Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement
Public Health Agency of Canada, regarding the federal response to the hepatitis C virus.
Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.
Communications with Health Canada regarding the application of its nitrosamine guidelines.
Communications with Health Canada regarding guidelines for pediatric action plans.
Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.
Communications regarding national pharmacare legislation, regulations, policies or programs.
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada.
Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
Communications regarding the design and implementation of the federal Drugs for Rare Diseases strategy.